In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Recent studies indicated that bone marrow mesenchymal stem cells (BM-MSCs) derived from multiple myeloma (MM) patients were different from those of normal subjects in a variety of aspects. However, it is largely unknown whether BM-MSCs derived from MM patients display any aberrant chemotactic migration. To this aim, we compared the chemotactic migration of BM-MSCs derived from MM patients with those from normal subjects. Our results showed that BM-MSCs derived from MM patients migrated more vigorously to myeloma cell line. Furthermore, proteasome inhibitor bortezomib was showed to suppress chemotactic migration of BM-MSCs whatever their origins. However, although the chemotactic migration of BM-MSCs derived from MM patients to myeloma cell line was more significantly suppressed by bortezomib treatment, migration to SDF-1 or FBS of BM-MSCs was less compromised. Both SDF-1 and TNF-α enhanced phosphorylation of iκ-Bα in BM-MSCs. Although bortezomib significantly inhibited the iκ-Bα phosphorylation by SDF-1, it had little effect on iκ-Bα phosphorylation by TNF-α. Collectively, our results suggested that aberrant chemotactic migration of BM-MSCs derived from MM patients and the possible migration-regulatory role of bortezomib treatment.
Department of Hematology, Affiliated Hospital of Jiangsu University, Jiangsu University Zhenjiang, Jiangsu Province, P.R. China.
Xinxin
X
Xu
Department of Hematology, Affiliated Hospital of Jiangsu University, Jiangsu University Zhenjiang, Jiangsu Province, P.R. China.
Jiao
J
Yang
Department of Rheumatology, Affiliated Hospital of Jiangsu University, Jiangsu University Zhenjiang, Jiangsu Province, P.R. China.
Yu
Y
Tang
Department of Hematology, First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu Province, P.R. China.
Junxia
J
Li
Department of Hematology, Affiliated Hospital of Jiangsu University, Jiangsu University Zhenjiang, Jiangsu Province, P.R. China.
Yan
Y
Zhu
Department of Hematology, First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu Province, P.R. China.
Hua
H
Lu
Department of Hematology, Affiliated Hospital of Jiangsu University, Jiangsu University Zhenjiang, Jiangsu Province, P.R. China ; Hematology Research Institute, Jiangsu University Jiangsu Province, Zhenjiang, P.R. China.
Xiaoming
X
Fei
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D054377:Chemokine CXCL12 / Q000494:pharmacology; D002633:Chemotaxis / Q000187:drug effects*; D018920:Coculture Techniques; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology*; D000072000:NF-KappaB Inhibitor alpha; D010766:Phosphorylation; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*; D044967:Serum / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000970:Antineoplastic Agents; D001897:Boronic Acids; D054377:Chemokine CXCL12; D020672:I-kappa B Proteins; C000606204:NFKBIA protein, human; D061988:Proteasome Inhibitors; D011719:Pyrazines; D014409:Tumor Necrosis Factor-alpha; D000072000:NF-KappaB Inhibitor alpha; D000069286:Bortezomib
Multiple myeloma; bone marrow mesenchymal stem cells; bortezomib; chemotactic migration